 | • レポートコード：MRC2Q12-19420 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥744,800 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,489,600 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、伝染性胃腸炎/豚流行性下痢ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 伝染性胃腸炎/豚流行性下痢ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 伝染性胃腸炎/豚流行性下痢ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 伝染性胃腸炎/豚流行性下痢ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの伝染性胃腸炎/豚流行性下痢ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の伝染性胃腸炎/豚流行性下痢ワクチンの売上および2028年までの予測に焦点を当てています。 伝染性胃腸炎/豚流行性下痢ワクチンのグローバル主要企業には、CNADC、Harbin Pharm、DBN、Ringpu、Wuhan Zhongbo Biology、Nannong Hi-tech、HPBG、Huizhong Biolgoical、Qilu Animal Health、Haid Group、Zhenye Biologcal、Tecbond、Jilin Teyan Biolgoical、Nisseiken、KM Biologicsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 伝染性胃腸炎/豚流行性下痢ワクチン市場は、タイプとアプリケーションによって区分されます。世界の伝染性胃腸炎/豚流行性下痢ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 伝染性胃腸炎/豚流行性下痢ワクチン、生ワクチン、伝染性胃腸炎/豚流行性下痢ワクチン、不活化 【アプリケーション別セグメント】 農場、個人 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 伝染性胃腸炎/豚流行性下痢ワクチン製品概要 - タイプ別市場（伝染性胃腸炎/豚流行性下痢ワクチン、生ワクチン、伝染性胃腸炎/豚流行性下痢ワクチン、不活化） - アプリケーション別市場（農場、個人） - 調査の目的 ・エグゼクティブサマリー - 世界の伝染性胃腸炎/豚流行性下痢ワクチン販売量予測2017-2028 - 世界の伝染性胃腸炎/豚流行性下痢ワクチン売上予測2017-2028 - 伝染性胃腸炎/豚流行性下痢ワクチンの地域別販売量 - 伝染性胃腸炎/豚流行性下痢ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別伝染性胃腸炎/豚流行性下痢ワクチン販売量 - 主要メーカー別伝染性胃腸炎/豚流行性下痢ワクチン売上 - 主要メーカー別伝染性胃腸炎/豚流行性下痢ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（伝染性胃腸炎/豚流行性下痢ワクチン、生ワクチン、伝染性胃腸炎/豚流行性下痢ワクチン、不活化） - 伝染性胃腸炎/豚流行性下痢ワクチンのタイプ別販売量 - 伝染性胃腸炎/豚流行性下痢ワクチンのタイプ別売上 - 伝染性胃腸炎/豚流行性下痢ワクチンのタイプ別価格 ・アプリケーション別市場規模（農場、個人） - 伝染性胃腸炎/豚流行性下痢ワクチンのアプリケーション別販売量 - 伝染性胃腸炎/豚流行性下痢ワクチンのアプリケーション別売上 - 伝染性胃腸炎/豚流行性下痢ワクチンのアプリケーション別価格 ・北米市場 - 北米の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの伝染性胃腸炎/豚流行性下痢ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの伝染性胃腸炎/豚流行性下痢ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の伝染性胃腸炎/豚流行性下痢ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 CNADC、Harbin Pharm、DBN、Ringpu、Wuhan Zhongbo Biology、Nannong Hi-tech、HPBG、Huizhong Biolgoical、Qilu Animal Health、Haid Group、Zhenye Biologcal、Tecbond、Jilin Teyan Biolgoical、Nisseiken、KM Biologics ・産業チェーン及び販売チャネル分析 - 伝染性胃腸炎/豚流行性下痢ワクチンの産業チェーン分析 - 伝染性胃腸炎/豚流行性下痢ワクチンの原材料 - 伝染性胃腸炎/豚流行性下痢ワクチンの生産プロセス - 伝染性胃腸炎/豚流行性下痢ワクチンの販売及びマーケティング - 伝染性胃腸炎/豚流行性下痢ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 伝染性胃腸炎/豚流行性下痢ワクチンの産業動向 - 伝染性胃腸炎/豚流行性下痢ワクチンのマーケットドライバー - 伝染性胃腸炎/豚流行性下痢ワクチンの課題 - 伝染性胃腸炎/豚流行性下痢ワクチンの阻害要因 ・主な調査結果 |
Biologics for the prevention of infectious gastroenteritis in pigs and epidemic diarrhea in pigs
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine include CNADC, Harbin Pharm, DBN, Ringpu, Wuhan Zhongbo Biology, Nannong Hi-tech, HPBG, Huizhong Biolgoical and Qilu Animal Health, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine market. Further, it explains the major drivers and regional dynamics of the global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
CNADC
Harbin Pharm
DBN
Ringpu
Wuhan Zhongbo Biology
Nannong Hi-tech
HPBG
Huizhong Biolgoical
Qilu Animal Health
Haid Group
Zhenye Biologcal
Tecbond
Jilin Teyan Biolgoical
Nisseiken
KM Biologics
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by activity and by downstream segments based on sales, price, and value for the period 2017-2028.
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Segment by Activity
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Live
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Inactivated
Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Segment by Downstream
Farms
Individual
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CNADC, Harbin Pharm, DBN, Ringpu, Wuhan Zhongbo Biology, Nannong Hi-tech, HPBG, Huizhong Biolgoical and Qilu Animal Health, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by activity, by downstream and by country, sales and revenue for each segment.
Chapter 7: Europe by activity, by downstream and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by activity, by downstream and by country, sales and revenue for each segment.
Chapter 9: Latin America by activity, by downstream and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by activity, by downstream and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Introduction
1.2 Market by Activity
1.2.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size Growth Rate by Activity, 2017 VS 2021 VS 2028
1.2.2 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Live
1.2.3 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine, Inactivated
1.3 Market by Downstream
1.3.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size Growth Rate by Downstream, 2017 VS 2021 VS 2028
1.3.2 Farms
1.3.3 Individual
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Region
2.4.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine by Region (2023-2028)
2.5 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Region
2.5.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Region (2017-2022)
2.5.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Manufacturers
3.1.1 Global Top Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine in 2021
3.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Manufacturers
3.2.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue in 2021
3.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Activity
4.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity
4.1.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Historical Sales by Activity (2017-2022)
4.1.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Forecasted Sales by Activity (2023-2028)
4.1.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Market Share by Activity (2017-2028)
4.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity
4.2.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Historical Revenue by Activity (2017-2022)
4.2.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Forecasted Revenue by Activity (2023-2028)
4.2.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue Market Share by Activity (2017-2028)
4.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price by Activity
4.3.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price by Activity (2017-2022)
4.3.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price Forecast by Activity (2023-2028)
5 Market Size by Downstream
5.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream
5.1.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Historical Sales by Downstream (2017-2022)
5.1.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Forecasted Sales by Downstream (2023-2028)
5.1.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Market Share by Downstream (2017-2028)
5.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream
5.2.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Historical Revenue by Downstream (2017-2022)
5.2.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Forecasted Revenue by Downstream (2023-2028)
5.2.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue Market Share by Downstream (2017-2028)
5.3 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price by Downstream
5.3.1 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price by Downstream (2017-2022)
5.3.2 Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Price Forecast by Downstream (2023-2028)
6 North America
6.1 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Activity
6.1.1 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity (2017-2028)
6.1.2 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity (2017-2028)
6.2 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Downstream
6.2.1 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream (2017-2028)
6.2.2 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream (2017-2028)
6.3 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Country
6.3.1 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Country (2017-2028)
6.3.2 North America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Activity
7.1.1 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity (2017-2028)
7.1.2 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity (2017-2028)
7.2 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Downstream
7.2.1 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream (2017-2028)
7.2.2 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream (2017-2028)
7.3 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Country
7.3.1 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Country (2017-2028)
7.3.2 Europe Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Activity
8.1.1 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity (2017-2028)
8.1.2 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity (2017-2028)
8.2 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Downstream
8.2.1 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream (2017-2028)
8.2.2 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream (2017-2028)
8.3 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Region
8.3.1 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Activity
9.1.1 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity (2017-2028)
9.1.2 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity (2017-2028)
9.2 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Downstream
9.2.1 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream (2017-2028)
9.2.2 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream (2017-2028)
9.3 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Country
9.3.1 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Activity
10.1.1 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Activity (2017-2028)
10.1.2 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Activity (2017-2028)
10.2 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Downstream
10.2.1 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Downstream (2017-2028)
10.2.2 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Downstream (2017-2028)
10.3 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Size by Country
10.3.1 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CNADC
11.1.1 CNADC Corporation Information
11.1.2 CNADC Overview
11.1.3 CNADC Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CNADC Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CNADC Recent Developments
11.2 Harbin Pharm
11.2.1 Harbin Pharm Corporation Information
11.2.2 Harbin Pharm Overview
11.2.3 Harbin Pharm Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Harbin Pharm Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Harbin Pharm Recent Developments
11.3 DBN
11.3.1 DBN Corporation Information
11.3.2 DBN Overview
11.3.3 DBN Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 DBN Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 DBN Recent Developments
11.4 Ringpu
11.4.1 Ringpu Corporation Information
11.4.2 Ringpu Overview
11.4.3 Ringpu Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Ringpu Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ringpu Recent Developments
11.5 Wuhan Zhongbo Biology
11.5.1 Wuhan Zhongbo Biology Corporation Information
11.5.2 Wuhan Zhongbo Biology Overview
11.5.3 Wuhan Zhongbo Biology Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Wuhan Zhongbo Biology Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Wuhan Zhongbo Biology Recent Developments
11.6 Nannong Hi-tech
11.6.1 Nannong Hi-tech Corporation Information
11.6.2 Nannong Hi-tech Overview
11.6.3 Nannong Hi-tech Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Nannong Hi-tech Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Nannong Hi-tech Recent Developments
11.7 HPBG
11.7.1 HPBG Corporation Information
11.7.2 HPBG Overview
11.7.3 HPBG Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 HPBG Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 HPBG Recent Developments
11.8 Huizhong Biolgoical
11.8.1 Huizhong Biolgoical Corporation Information
11.8.2 Huizhong Biolgoical Overview
11.8.3 Huizhong Biolgoical Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Huizhong Biolgoical Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Huizhong Biolgoical Recent Developments
11.9 Qilu Animal Health
11.9.1 Qilu Animal Health Corporation Information
11.9.2 Qilu Animal Health Overview
11.9.3 Qilu Animal Health Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Qilu Animal Health Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Qilu Animal Health Recent Developments
11.10 Haid Group
11.10.1 Haid Group Corporation Information
11.10.2 Haid Group Overview
11.10.3 Haid Group Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Haid Group Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Haid Group Recent Developments
11.11 Zhenye Biologcal
11.11.1 Zhenye Biologcal Corporation Information
11.11.2 Zhenye Biologcal Overview
11.11.3 Zhenye Biologcal Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Zhenye Biologcal Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Zhenye Biologcal Recent Developments
11.12 Tecbond
11.12.1 Tecbond Corporation Information
11.12.2 Tecbond Overview
11.12.3 Tecbond Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Tecbond Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Tecbond Recent Developments
11.13 Jilin Teyan Biolgoical
11.13.1 Jilin Teyan Biolgoical Corporation Information
11.13.2 Jilin Teyan Biolgoical Overview
11.13.3 Jilin Teyan Biolgoical Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Jilin Teyan Biolgoical Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Jilin Teyan Biolgoical Recent Developments
11.14 Nisseiken
11.14.1 Nisseiken Corporation Information
11.14.2 Nisseiken Overview
11.14.3 Nisseiken Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Nisseiken Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Nisseiken Recent Developments
11.15 KM Biologics
11.15.1 KM Biologics Corporation Information
11.15.2 KM Biologics Overview
11.15.3 KM Biologics Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 KM Biologics Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 KM Biologics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Industry Chain Analysis
12.2 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Production Mode & Process
12.4 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales and Marketing
12.4.1 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Sales Channels
12.4.2 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Distributors
12.5 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Industry Trends
13.2 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Drivers
13.3 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Challenges
13.4 Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Market Restraints
14 Key Findings in The Global Transmissible Gastroenteritis and Porcine Epidemic Diarrhea Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【伝染性胃腸炎/豚流行性下痢ワクチンについて】 ※伝染性胃腸炎（Transmissible Gastroenteritis, TGE）は、主に豚に影響を与えるウイルス性疾患であり、特に子豚において重篤な症状を引き起こします。この疾患は、豚の腸管に感染し、急性の腹下痢や脱水症状を引き起こすことから、豚の飼育産業において深刻な影響を及ぼす要因となります。一方、豚流行性下痢（Porcine Epidemic Diarrhea, PED）は、同様に豚に影響を及ぼす疾患であり、特に2013年以降、北アメリカを中心に大流行しました。 これらの疾患は、いずれもコロナウイルスによって引き起こされます。TGEウイルスとPEDウイルスは異なるが、似たような症状を呈し、感染力が非常に高いのが特徴です。感染した豚は、嘔吐や水様性下痢を示し、特に若齢の子豚にとっては致死率が非常に高いことが懸念されます。このような背景から、これらの病気に対するワクチン開発が重要視されてきました。 伝染性胃腸炎と豚流行性下痢のワクチンには、主に4つの種類があります。第一に、死菌または不活化ワクチンです。これは、ウイルスを化学的に不活化し、免疫反応を引き起こすことを目的としています。施工が比較的簡単で、安全性が高いことがメリットですが、免疫効果が短期間であるため、ブースター接種が必要です。 第二に、減弱生ワクチンがあります。このワクチンはウイルスを弱毒化することにより、感染を模倣する形で免疫反応を引き起こします。効果的な免疫を提供しますが、うまく管理されないと、弱毒株が事故的に感染するリスクがあります。 第三のタイプは、組換えタンパク質ワクチンです。これは遺伝子工学を用いて特定のウイルス抗原を発現させる技術です。感染のリスクが少なく、選択的な免疫応答を誘導することが可能です。しかし、開発と製造には高度な技術と設備が必要です。 最後に、mRNAワクチンのような新しい方式も考案されています。mRNAワクチンは、細胞にウイルスのスパイクタンパク質の設計図を提供し、体内でそれを作り出すことで免疫を獲得します。このタイプのワクチンは迅速に開発できる利点がありますが、冷蔵保存が必要なため流通に制約があります。 これらのワクチンは、主に豚の出産前や出産後の防疫対策として使用されます。特に、妊豚に対してワクチン接種を行うことで、母豚から子豚への抗体移行を促進し、子豚が生後間もなく獲得する免疫を強化します。この戦略により、子豚の生存率を向上させることが期待できます。 さらには、関連技術として、病原体の迅速診断技術や感染管理手法の向上も重要です。分子生物学的手法やPCR（ポリメラーゼ連鎖反応）技術を用いた迅速診断により、感染の早期発見が可能になります。これにより、感染拡大を防ぎ、より効果的なワクチン接種が行えるようになります。 さらに、ファーミングシステムの改善やバイオセキュリティ対策も重要です。病原体が農場に侵入しないよう、衛生管理を徹底することが、これらの病気の予防には欠かせません。教育や啓発活動を通じて、農場経営者や従業員に対して、これらの疾患の理解を深めることも必要です。 伝染性胃腸炎や豚流行性下痢は、豚の健康や生産性に大きな影響を与える重大な問題ですが、適切なワクチン接種と病気管理技術を駆使することで、そのリスクを軽減することが可能です。農業の現場での取り組みと研究開発の進展によって、今後の豚の健康管理が一層進化することが期待されます。このように、教育、技術、ワクチンの進化は、豚の健康と持続可能な生産に向けた重要な要素であると言えるでしょう。 |